As an active SPAC through 2024, Pono Capital Two targeted technology-enabled opportunities in the Japanese market, leveraging sponsor expertise in both US and Asia-Pacific sectors. Post-merger integration with SBC Medical Group represents the company's transition from acquisition vehicle to operating healthcare company.
Cyborg Score Rationale
Pono Capital Two faced significant operational challenges as an active SPAC, including falling below the minimum 1.1 million shares outstanding requirement for continued Nasdaq listing in April 2024. The post-merger SBC Medical entity has experienced shareholder value loss.